Protara Therapeutics Analyst Ratings
Protara Therapeutics (TARA) Receives a Buy From Oppenheimer
Protara Therapeutics Analyst Ratings
Protara Therapeutics Analyst Ratings
Protara Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Oppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)
Analysts Conflicted on These Healthcare Names: Protara Therapeutics (TARA), Cybin (CYBN) and Roche Holding AG (OtherRHHVF)
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amarin (AMRN), Protara Therapeutics (TARA) and Incyte (INCY)
Oppenheimer Remains a Buy on Protara Therapeutics (TARA)
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Protara Therapeutics Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Protara Therapeutics (TARA)
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
H.C. Wainwright Reaffirms Their Buy Rating on Protara Therapeutics (TARA)
HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating
H.C. Wainwright Keeps Their Buy Rating on Protara Therapeutics (TARA)
No Data